악성 중피종 시장 규모, 점유율, 성장 분석 : 시판약별, 후기 개발 단계 파이프라인약별, 지역별 - 업계 예측(2026-2033년)

Malignant Mesothelioma Market size was valued at USD 171.97 Million in 2024 and is poised to grow from USD 181.78 Million in 2025 to USD 283.23 Million by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).

The significant impact of malignant mesothelioma patient advocacy groups and support networks underscores their crucial role in combating this cancer. These organizations enhance awareness and promote early diagnosis, thereby improving outcomes for affected individuals. Their dedicated efforts in advocacy, education, and outreach are vital in improving patient care, ensuring that those impacted by mesothelioma receive the necessary support and resources for their journey. As a result, these networks not only empower patients but also foster a community of understanding and assistance, highlighting the importance of collaborative efforts in addressing the challenges posed by this aggressive disease. Enhanced engagement from these groups contributes to better-informed patients and a supportive environment, essential for navigating the complexities of mesothelioma treatment and care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Malignant Mesothelioma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Malignant Mesothelioma Market Segments Analysis

Global Malignant Mesothelioma Market is segmented by In-Market Drugs, Late-Stage Pipeline Drugs and region. Based on In-Market Drugs, the market is segmented into Mechanism of Action, Regulatory Status, Clinical Trial Results and Drug Uptake and Market Performance. Based on Late-Stage Pipeline Drugs, the market is segmented into Mechanism of Action, Regulatory Status, Clinical Trial Results and Drug Uptake and Market Performance. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Malignant Mesothelioma Market

The increasing advancements in diagnostic techniques significantly contribute to the growth of the malignant mesothelioma market. Enhanced methods and tools for detecting this particular type of cancer have seen remarkable improvements, facilitating more accurate identification of cases. Furthermore, rising awareness among healthcare professionals and the general public about the disease has fostered earlier detection and diagnosis. Consequently, a greater number of cases are being recognized and diagnosed at an initial stage, which not only elevates the demand for treatment options but also emphasizes the importance of ongoing research and development in this area.

Restraints in the Malignant Mesothelioma Market

Malignant mesothelioma is marked by an extended latency period, often lasting several decades from the initial exposure to asbestos to the onset of symptoms. This lengthy interval creates significant obstacles, as it hinders the ability to identify the disease early and implement timely treatment for those at risk. The delay in symptom manifestation can result in advanced disease stages by the time diagnosis occurs, complicating the therapeutic approach and reducing the chances of successful intervention. Consequently, the protracted nature of this condition serves as a considerable restraint within the market for malignant mesothelioma, impacting both patient outcomes and healthcare strategies.

Market Trends of the Malignant Mesothelioma Market

The malignant mesothelioma market is notably influenced by the aging population, resulting in heightened incidence rates of this aggressive cancer primarily affecting older adults. With a significant portion of the global demographic experiencing longer life expectancies, the number of individuals diagnosed with mesothelioma is predicted to surge. This trend is compounded by the disease's long latency period, where symptoms may emerge decades after asbestos exposure, intensifying the urgency for advanced diagnostic and therapeutic interventions. Consequently, pharmaceutical companies and healthcare providers are focusing on developing innovative treatment options and support systems to address the rising demand within this niche yet critical oncology market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Malignant Mesothelioma Market Size by In-Market Drugs & CAGR (2026-2033)

• Market Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Global Malignant Mesothelioma Market Size by Late-Stage Pipeline Drugs & CAGR (2026-2033)

• Market Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Global Malignant Mesothelioma Market Size & CAGR (2026-2033)

• North America (In-Market Drugs, Late-Stage Pipeline Drugs)
  • US
  • Canada
• Europe (In-Market Drugs, Late-Stage Pipeline Drugs)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (In-Market Drugs, Late-Stage Pipeline Drugs)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (In-Market Drugs, Late-Stage Pipeline Drugs)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (In-Market Drugs, Late-Stage Pipeline Drugs)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corden Pharma GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Concordia International Corp. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Hakko Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Polaris Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nichi-Iko Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations